{"id":"azilsartan-medoxomil-low-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL2028661","moleculeType":"Small molecule","molecularWeight":"568.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azilsartan medoxomil is a prodrug that is hydrolyzed to azilsartan, which competitively antagonizes angiotensin II type 1 (AT1) receptors on vascular smooth muscle and other tissues. By blocking AT1 receptor signaling, it prevents vasoconstriction and aldosterone secretion, leading to vasodilation and reduced sodium retention, thereby lowering blood pressure. The low-dose formulation provides a reduced therapeutic dose for patients requiring lower antihypertensive exposure.","oneSentence":"Azilsartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors to reduce blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:13.631Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT02235909","phase":"PHASE3","title":"An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension","status":"COMPLETED","sponsor":"Arbor Pharmaceuticals, Inc.","startDate":"2015-03-30","conditions":"Hypertension","enrollment":377},{"nctId":"NCT02235519","phase":"PHASE2, PHASE3","title":"Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients","status":"UNKNOWN","sponsor":"Hospital General de México Dr. Eduardo Liceaga","startDate":"2014-01","conditions":"Hypertension, Obesity, Type 2 Diabetes Mellitus","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AR14","AZM-L"],"phase":"phase_3","status":"active","brandName":"Azilsartan Medoxomil Low-dose","genericName":"Azilsartan Medoxomil Low-dose","companyName":"Arbor Pharmaceuticals, Inc.","companyId":"arbor-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azilsartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively blocks AT1 receptors to reduce blood pressure. Used for Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}